Skip to main content

Table 2 Treatment modalities and adverse events profile

From: The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?

Characteristic

N = 47 (N, %)

Up-front therapy

MPV ± R followed by WBRT + HIDAC

MPV ± R followed by HIDAC

WBRT isolated

Steroids ± intrathecal chemotherapy

23 (48.9)

17 (36.1)

04 (8.5)

03 (6.5)

Palliative or curative WBRT

27 (57.4)

 ≥ 1 line of therapy

10 (21.2)

ASCT consolidation

0 (0)

Infection

13 (27.6)

Febrile neutropenia

06 (12.7)

G3/G4 neutropenia

08 (17.0)

G3/G4 thrombocytopenia

06 (12.7)

G3/G4 acute kidney injury

08 (17.0)

G3/G4 mucositis

05 (10.6)

Dementia

03 (6.3)

  1. MPV methotrexate, procarbazine and vincristine, R rituximab, WBRT whole brain radiotherapy, HIDAC high-dose cytarabine, ASCT autologous hematopoietic stem cell transplantation, G3/G4 grade 3 or 4 toxicities (CTC version 4.0.)